Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥2,446 JPY
Change Today +25.00 / 1.03%
Volume 30.6K
4585 On Other Exchanges
Symbol
Exchange
Tokyo
As of 2:00 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

umn pharma inc (4585) Snapshot

Open
¥2,505
Previous Close
¥2,421
Day High
¥2,518
Day Low
¥2,446
52 Week High
09/10/14 - ¥3,950
52 Week Low
08/25/15 - ¥2,171
Market Cap
23.4B
Average Volume 10 Days
115.7K
EPS TTM
¥-482.13
Shares Outstanding
9.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for UMN PHARMA INC (4585)

Related News

No related news articles were found.

umn pharma inc (4585) Related Businessweek News

No Related Businessweek News Found

umn pharma inc (4585) Details

UMN Pharma Inc. develops and manufactures biopharmaceuticals in Japan and internationally. It develops UMN-0502, a seasonal influenza vaccine; UMN-0501 and UMN-0901, which are pandemic influenza vaccines; UMN-2003, a norovirus/rotavirus vaccine; and UMN-2002, a norovirus vaccine. The company was founded in 2004 and is headquartered in Yokohama, Japan.

96 Employees
Last Reported Date: 03/30/15
Founded in 2004

umn pharma inc (4585) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

umn pharma inc (4585) Key Developments

UMN Pharma Inc. Announces Consolidated Earnings Results for the Six Months Ended June 30, 2015; Revises Earnings Guidance for the Year Ending December 31, 2015

UMN Pharma Inc. announced consolidated earnings results for the six months ended June 30, 2015. For the period, the company's net sales were ¥45 million compared with ¥1,078 million a year ago. Operating loss was ¥2,157 million compared with ¥1,796 million a year ago. Ordinary loss was ¥2,186 million compared with ¥1,967 million a year ago. Net loss was ¥2,183 million or ¥228.17 per basic share compared with ¥1,677 million or ¥198.63 per basic share a year ago. Loss before income taxes and minority interests was ¥2,186.7 million compared with ¥1,720.5 million a year ago. Net cash used in operating activities was ¥1,700.3 million compared with net cash provided by operating activities of ¥2,280.6 million a year ago. This was mainly due to loss before income taxes of ¥2,186,674,000, depreciation of ¥762,709,000, increase in inventories of ¥820,738,000 and increase in notes and accounts payable-trade of ¥891,310,000. Purchase of property, plant and equipment was ¥14.7 million compared with ¥2.2 million a year ago. Purchase of intangible assets was ¥0.22 million compared with ¥3.1 million a year ago. For the year ending December 31, 2015, the company forecasts net sales of ¥2,254 million, operating loss of ¥1,697 million, ordinary loss of ¥1,844 million, net loss of ¥1,852 million or ¥193.54 per share compared to previous guidance of net sales of ¥5,224 million, operating loss of ¥878 million, ordinary loss of ¥1,025 million, net loss of ¥1,033 million or ¥108.14 per share.

UMN Pharma Inc. to Report Q2, 2015 Results on Jul 31, 2015

UMN Pharma Inc. announced that they will report Q2, 2015 results on Jul 31, 2015

UMN Pharma Inc., Q2 2015 Earnings Call, Aug 03, 2015

UMN Pharma Inc., Q2 2015 Earnings Call, Aug 03, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4585:JP ¥2,446.00 JPY +25.00

4585 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4585.
View Industry Companies
 

Industry Analysis

4585

Industry Average

Valuation 4585 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 317.1x
Price/Book 15.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 193.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UMN PHARMA INC, please visit www.umnpharma.com/en. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.